MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Halozyme Therapeutics ROE Ratio 2011-2026 | HALO
Annual ROE Ratio Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 649.18 | 122.06 | 336.0 | 119.04 | 204.47 | 85.46 | -78.72 | -32.28 | 30.22 | 317.18 | -74.96 | -165.35 | 417.59 | -109.62 | -181.37 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 649.18 | -181.37 | 109.26 |
Quarterly ROE Ratio Halozyme Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 139.16 | 134.65 | 117.23 | 105.69 | 138.53 | 141.11 | 158.39 | 142.5 | 206.04 | 236.75 | 194.99 | 94.38 | 171.27 | 184.62 | 253.26 | 194.54 | 242.97 | 190.05 | 130.77 | 85.46 | -0.46 | -51.69 | -84.72 | -78.72 | -42.09 | -26.02 | -19.28 | -32.28 | 28.03 | 40.54 | 34.98 | 30.22 | 55.08 | 142.88 | 240.38 | 317.18 | 169.18 | 12.74 | -132.5 | -239.59 | -188.66 | -170.38 | -147.23 | -165.35 | -42.61 | 102.94 | 256.91 | 417.6 | 298.6 | 161.14 | 17.82 | -109.62 | -269.53 | -181.2 | -123.91 | -181.36 | 47.39 | 28.59 | -88.4 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 417.6 | -269.53 | 55.74 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
89.06 | $ 349.36 | 2.75 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
-101.78 | $ 12.67 | 2.82 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 24.45 | 5.07 % | $ 3.11 B | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.47 | 8.17 % | $ 391 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.83 | 1.86 % | $ 9.21 B |  Australia |
 |
BioNTech SE
BNTX
|
1.11 | $ 91.3 | 1.87 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.72 | 5.84 % | $ 17.1 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.59 | 0.88 % | $ 742 M | Britain |
 |
Avid Bioservices
CDMO
|
-231.16 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-103.99 | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 3.07 | - | $ 308 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 3.08 | 1.65 % | $ 6.7 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
-24.33 | $ 1.93 | 4.89 % | $ 368 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.4 | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-71.33 | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
529.06 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-43.82 | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-255.25 | $ 2.82 | 2.55 % | $ 7.36 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-55.55 | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.58 | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Cyclerion Therapeutics
CYCN
|
-34.54 | $ 3.47 | -0.29 % | $ 8.74 M | USA |